Physicians' Academy for Cardiovascular Education

Response to anti-inflammatory treatment explains CV benefit in CANTOS trial

Presented at AHA 2017 Scientific Sessions in Anaheim, CA, USA by Paul Ridker (Brigham and Woman’s Hospital, Boston, MA, VS).

Nov. 13, 2017 - news

AHA 2017 A new analysis of CANTOS data shows that patients who achieved hsCRP < 2 mg/L benefitted from a reduction in MACE and mortality, irrespective of the dose of canakinumab.

Robust benefits for CV and limb event risk in PAD patients on PCSK9 inhibition

AHA 2017 - Anaheim, CA

Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Marc Bonaca - Boston, MA, USA
PAD patients enrolled in the FOURIER trial who were treated with PCKS9 inhibitor evolocumab showed a higher absolute and relative CV event reduction, and a large reduction in limb events.

AHA 2017 PAD patients enrolled in the FOURIER trial who were treated with PCKS9 inhibitor evolocumab showed a higher absolute and relative CV event reduction, and a large reduction in limb events.

Greater relative and absolute risk reduction in high-risk subgroup with previous MI treated with PCSK9 inhibition

AHA 2017 - Anaheim, CA, USA

Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Marc Sabatine - Boston, MA, VS
Subanalysis of FOURIER shows that within the subgroup of patients with prior MI, a subgroup at extra high risk has greater benefit of LDL-c lowering with PCSK9 inhibitor evolocumab.

AHA 2017 Subanalysis of FOURIER shows that within the subgroup of patients with prior MI, a subgroup at extra high risk has greater benefit of LDL-c lowering with PCSK9 inhibitor evolocumab.

Restrictive RBC transfusion strategy non-inferior to liberal approach in cardiac surgery

Presented at ACC.17 Scientific Sessions in Anaheim, CA, USA by C.David Mazer (University of Toronto, Toronto, Ont, Canada)

Nov. 13, 2017 - news

AHA 2017 A restrictive RBC transfusion strategy with 7.5 g/dL as trigger was non-inferior to a strategy with 9.5 g/dL for mortality and major morbidity in patients undergoing cardiac surgery in TRICS III.

DAPT improves patency of saphenous vein graft at 1 year post-CABG

Presented at ACC.17 Scientific Sessions in Anaheim, CA, USA by Qiang Zhao (Ruijin Hospital, Shanghai)

Nov. 13, 2017 - news
The small DACAB study demonstrated that DAPT with ticagrelor plus aspirin more often showed patency of SVG and was associated with numerically lower MACE at 1 year as compared with aspirin alone.

AHA 2017 The small DACAB study demonstrated that DAPT with ticagrelor plus aspirin more often showed patency of SVG and was associated with numerically lower MACE at 1 year as compared with aspirin alone.

Continuation or interruption of DOAC does not affect hematoma risk at device surgery

Presented at ACC.17 Scientific Sessions in Anaheim, CA, USA by David H. Birnie (Ottawa Heart Institute, Ottawa, ON, Canada)

Nov. 13, 2017 - news
BRUISE CONTROL 2 was a blinded randomized trial that compared periprocedural continuation or interruption of DOAC therapy and found similarly low rates of CVA/TIA and hematoma.

AHA 2017 BRUISE CONTROL 2 was a blinded randomized trial that compared periprocedural continuation or interruption of DOAC therapy and found similarly low rates of CVA/TIA and hematoma.

Higher nonfasting triglycerides increase the risk of heart failure

Nov. 9, 2017 - Varbo A and Nordestgaard BG. - ATVB 2018

Stepwise higher concentrations of nonfasting triglycerides were associated with a stepwise higher risk of heart failure, which was not the case for LDL-c.

Patients with severe hypertriglyceridemia benefit from omega-3 carboxylic acids 2 g/day

Nov. 9, 2017 - Stroes ESG, et al. - J Clin Lipidol 2017

Patients with SHTG treated with OM3-CA 2 g daily had a statistically significant reduction in TG and non-HDL-c concentrations compared with those treated with olive oil 2 g daily.

Meeting Impression | Modern Management of Diabetes in Cardiology: Impact of SGLT2 Inhibition on CV Outcomes and Heart Failure

August 28, 2017 - ESC
August 28, 2017 - ESC

In this educational program, which was held at the ESC Congress 2017 in Barcelona, Spain, the role of diabetes treatment in the management of heart failure, as well as novel interventions targeted to improve CV outcomes were discussed.

Summary | Heart failure & Diabetes: Time for a more unified approach

August 28, 2017 - Prof. Stefan Anker (Berlin, Germany)
August 28, 2017 - Prof. Stefan Anker (Berlin, Germany)

Lessons learned from the EMPA-REG OUTCOME trial: prof Anker suggested that empagliflozin may prevent the development of HF. However, he emphasized that new trials are needed to test the effect of SGLT2 inhibitors in the treatment of HF in diabetes patients.

Summary | Management of CV Risk & T2DM: Implications of novel outcome trials

August 28, 2017 - Prof. John Deanfield (London, UK)
August 28, 2017 - Prof. John Deanfield (London, UK)

A summary of the beneficial effects of the SGLT2 inhibitor empagliflozin and GLP-1 receptor agonist liraglutide on CV outcome in patients with diabetes and CVD was given by prof. Deanfield. He raised the point that this is a new era for CVD management in diabetes patients and discussed current and future studies.

AF patients receiving oral anticoagulation have a lower risk of dementia

Nov. 8, 2017 - Friberg L & Rosenqvist M - Eur Heart J 2017

In a large retrospective cohort study, the risk of dementia was higher without oral anticoagulant treatment in patients with AF, compared with AF patients receiving oral anticoagulation.

Agenda